Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

Max Bayer

Pharma Reporter

Pfizer’s next deals are likely to be longer-term efforts to reload its R&D work rather than big-ticket, late-stage assets, the company’s top executives said Tuesday …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

New study will try to stop Alzheimer’s decades before it begins, using experimental Eli Lilly drug

Updated: RFK Jr. advances out of Senate committee with Cassidy’s support

We’re about to find out which RFK Jr. will show up at HHS

Astellas shakes up management despite impressive nine-month earnings

Flagship spinout Omega is days away from bankruptcy, filing shows

Regeneron will start delivering quarterly dividends 37 years into its existence

Pfiz­er says it has at least $10B avail­able for deals in 2025, with a fo­cus on pipeline

Pharma Reporter

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline